Immediate (IgE-mediated) skin testing in the diagnosis of allergic disease.
Immediate (IgE-mediated) skin tests are widely used in the diagnosis of allergic diseases. Skin tests correlate well with more specialized studies (RAST, histamine release and provocation tests) in the diagnosis of allergic disease. Lack of standardization and quantitation of biologic potency of allergens make critical comparison of skin test results impossible. A survey of practicing allergists yielded widely divergent opinions concerning the effect of anti-allergic drugs on skin tests. The results of published studies indicate that only antihistamines cause significant depression of skin reactivity. Therefore, therapy for asthma may be continued while diagnostic skin testing is in progress, avoiding the possible morbidity associated with discontinuing pharmacologic therapy.
D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000485:Allergens / Q000592:standards; D001507:Beclomethasone / Q000494:pharmacology; D006306:Health Surveys; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D006636:Histamine Release / Q000187:drug effects; D006801:Humans; D006967:Hypersensitivity / Q000175:diagnosis*; D006969:Hypersensitivity, Immediate / Q000175:diagnosis*; D007073:Immunoglobulin E; D011241:Prednisone / Q000494:pharmacology; D011852:Radioallergosorbent Test; D012882:Skin Tests
D000318:Adrenergic beta-Agonists; D000485:Allergens; D006634:Histamine H1 Antagonists; D007073:Immunoglobulin E; D001507:Beclomethasone; D011241:Prednisone